Skip to main content
. Author manuscript; available in PMC: 2020 Feb 19.
Published in final edited form as: Anal Chem. 2019 Feb 6;91(4):2805–2812. doi: 10.1021/acs.analchem.8b04699

Figure 7.

Figure 7.

nRPLC and mass spectra for commercial ADC: brentuximab vedotin. (a) nRPLC with detection at 280 nm. Conditions same as those in Figure 4. (b) Raw mass spectra for D2, D4(1,2,3), D6, and D8, with the molecular weight based on deconvoluted mass spectra.